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Accepted 20 December 2017; Published online 28 December 2017AbstractObjectives: There is increasing recognition that insufficient attention has been paid to the choice of outcomes measured in clinical
trials. The lack of a standardized outcome classification system results in inconsistencies due to ambiguity and variation in how outcomes
are described across different studies. Being able to classify by outcome would increase efficiency in searching sources such as clinical trial
registries, patient registries, the Cochrane Database of Systematic Reviews, and the Core Outcome Measures in Effectiveness Trials
(COMET) database of core outcome sets (COS), thus aiding knowledge discovery.
Study Design and Setting: A literature review was carried out to determine existing outcome classification systems, none of which
were sufficiently comprehensive or granular for classification of all potential outcomes from clinical trials. A new taxonomy for outcome
classification was developed, and as proof of principle, outcomes extracted from all published COS in the COMET database, selected Co-
chrane reviews, and clinical trial registry entries were classified using this new system.
Results: Application of this new taxonomy to COS in the COMET database revealed that 274/299 (92%) COS include at least one
physiological outcome, whereas only 177 (59%) include at least one measure of impact (global quality of life or some measure of func-
tioning) and only 105 (35%) made reference to adverse events.
Conclusions: This outcome taxonomy will be used to annotate outcomes included in COS within the COMET database and is currently
being piloted for use in Cochrane Reviews within the Cochrane Linked Data Project. Wider implementation of this standard taxonomy
in trial and systematic review databases and registries will further promote efficient searching, reporting, and classification of trial
outcomes.  2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).
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Classification; Comparative effectiveness research1. Background
Recognition that insufficient attention has been paid to
the choice of outcomes to measure in clinical trials is
increasing. In the context of clinical trials, an outcome isFunding: S.D. and P.R.W. are funded by MRC North West Hub for
Trials Methodology Research MR/K025635/1. P.R.W. and M.C. are the
members of the COMET Management Group.
* Corresponding author. Department of Biostatistics, University of
Liverpool, Block F Waterhouse Building, 1-5 Brownlow Street, Liverpool,
L63 3GL, UK. Tel.: 0151 794 9758; fax: 0151 795 8770.
E-mail address: prw@liverpool.ac.uk (P.R. Williamson).
https://doi.org/10.1016/j.jclinepi.2017.12.020
0895-4356/ 2018 The Authors. Published by Elsevier Inc. This is an open acces
4.0/).defined to be a measurement or observation used to cap-
ture and assess the effect of treatment such as assessment
of side effects (risk) or effectiveness (benefits) [1]. The
Core Outcome Measures in Effectiveness Trials (COMET)
Initiative [E1], [2] brings together people interested in the
development and application of agreed standardized sets of
outcomes, known as ‘‘core outcome sets’’ (COS). These
sets represent the minimum that should be measured and
reported in all clinical trials of a specific condition and
are also suitable for use in clinical audit or research other
than randomized trials. One of the successes of COMET
has been the development of a publicly availables article under the CC BY license (http://creativecommons.org/licenses/by/
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Key findings
 Existing taxonomy structures are intended as gen-
eral health research vocabularies, rather than
focusing on outcomes; do not provide sufficiently
granular or comprehensive classification of trial
outcomes; or are disease specific or focused on
patient-centered outcomes only.
 The current lack of an outcome classification system,
fit for purpose, is holding back research as a result of
(i) inconsistency and ambiguity in how outcomes are
described across different studies and (ii) ineffi-
ciency in searching knowledge sources including
the published literature and ongoing research repos-
itories such as clinical trials registries, which to date
include outcomes as free-text entries only.
 A new workable outcome taxonomy is proposed,
the robustness of which has been demonstrated
through application to a large number of trial reg-
istry entries in clinicaltrials.gov, Cochrane
Reviews, and core outcome sets in the Core
Outcome Measures in Effectiveness Trials
(COMET) database.
What this adds to what was known?
 Core outcome set developers should give more
attention to measures of life impact and adverse
events when determining core outcome sets for tri-
als of the effectiveness of health and social care
interventions.
What is the implication and what should
change now?
 An accepted taxonomy of outcomes would in-
crease the reuse value of outcome data, just as
Medical Subject Headings terms have transformed
the searchability of medical literature. Wider im-
plementation of this taxonomy will help to reduce
waste in research by promoting efficient searching,
reporting, and classification of clinical outcomes
for the first time, thereby speeding up research ac-
tivities including discovery science and ‘‘big data’’
approaches to extracting knowledge from pub-
lished information.
searchable database of completed and ongoing projects in
COS development [2e7]. This unique resource provides in-
formation on the COS developed to date and is currently
searchable by population, intervention, and condition.
However, as yet the records in the COMET database have
not been categorized according to outcome, the fourth of
S. Dodd et al. / Journal of Clinthe essential elements that should be defined for a trial, ac-
cording to the population, intervention, comparison,
outcome (PICO) model.
Similarly, outcomes in trial registries (including the
EU Clinical Trials Register, ClinicalTrials.gov and
ISRCTN registry) can be entered as free text only,
hampering the ability to search for outcomes effectively
because of variation and inconsistencies in how out-
comes are described across different trials. Over 60%
queries related to requests to register a trial relate to
how outcomes were described [8]. Standardized termi-
nology to describe outcomes is starting to come into
use in preclinical research, where variations in descrip-
tion have impeded computational analysis of phenotypic
data [9]. However, there is currently no consensus on
how clinical trial outcomes should be classified. Standard
terminology to describe outcomes in preclinical and clin-
ical research would facilitate the comparison of out-
comes between preclinical and clinical settings,
potentially providing insight into the reasons why so
many late-phase trials ‘‘fail’’ despite promising results
from preclinical studies.
A taxonomy is a scheme of classification that is often
used for, for example, the naming of living organisms
but which can also be used as a controlled vocabulary
(i.e., an authoritative list of terms for use in indexing)
with a hierarchical structure [E2]. Taxonomies exist for
many aspects of health research, such as the Interna-
tional Classification of Functioning, Disability and
Health, (ICF [E3]) and International Statistical Classifi-
cation of Diseases and Related Health Problems 10th
Revision (ICD-10, [E4]). The Cochrane Linked Data
Project [E5] uses a 15-item taxonomy for high-level
categorization of interventions (for the IC components
of PICO).
A standard outcome taxonomy would help to
improve knowledge discovery by facilitating organized
searching of trials by outcome in trial registries and da-
tabases. For example, a researcher might be interested
in identifying all interventions that have been tested in
a randomized trial to improve a particular outcome.
Similarly, COS have the potential to reduce research
waste by avoiding unnecessary duplication of efforts
and allowing the results of clinical trials to be combined
[2,7], but this benefit will only be realized with COS
uptake. Classification of trial outcomes will facilitate
efficient assessment of COS uptake, again improving
knowledge [10].
We sought to identify and further develop as necessary a
taxonomy providing sufficient granularity and scope for the
classification of all outcomes in the COS listed in the
COMET database, which would be equally suitable for
classification of outcomes included in trial registries, trial
reports, and systematic reviews. This taxonomy is intended
for the classification of what, rather than how, outcomes are
measured.
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A suitable taxonomy for clinical trial outcomes must
clearly differentiate between high-level outcome types,
while comprehensively covering all potential outcomes
from clinical trials in a sensible hierarchical structure. We
carried out a literature review to identify existing outcome
taxonomies that would inform the development of the one
presented here. We searched PubMed for published journal
articles and Internet resources such as Google. Our search
involved a combination of terms, including ‘‘ontology’’,
‘‘taxonomy’’, ‘‘classification’’ or ‘‘categorisation’’ and
‘‘health’’, ‘‘health research’’, ‘‘trial’’, and ‘‘outcomes’’.
To examine outcome classification systems used as part
of COS development, the COS studies within the COMET
database that included a systematic or literature review to
identify relevant studies were reviewed to determine how
they categorized their outcomes.
The lack of an existing suitable outcome taxonomy for
trial outcomes led to the subsequent development of a
new taxonomy to classify trial and systematic review out-
comes. This was an iterative process, starting with the
15-category scale developed by Smith et al. [11] to classify
outcomes recorded in Cochrane Reviews (Table 1). A
refined version of this scale, developed by two authors
(P.R.W. and M.C.), was piloted as part of PICO classifica-
tion of reviews within the Cochrane database [E5]. This 12-
category version was then further developed to provide
more detail relating to physiological, function, and resource
use domains, leading to a taxonomy with 38 outcome do-
mains within five core areas. Explanations and examples
of outcomes within each of these domains are found in
Supplementary Table 1 on the journal’s web site at www.
elsevier.com.
Physiological outcomes are categorized according to the
underlying cause or affected body system, grouped using
the MedDRA System Organ Classes (SOCs)
(Supplementary Table 2 on the journal’s web site at
www.elsevier.com) with the exception of four SOCs (Inves-
tigations, Social circumstances, Surgical and medical pro-
cedures, Product issues) which are not considered
relevant within the physiological/clinical domains. For
example, ‘‘endocrine outcomes’’ are those associated with
endocrine disorders. ‘‘Outcomes related to neoplasms’’
include those relating to physiological function, signs and
symptoms caused by benign, malignant and unspecified
(including cysts and polyps) neoplasms, including solid
and nonsolid tumors. Examples of such outcomes include
‘‘time to recurrence’’, ‘‘response rate’’, and ‘‘clearance of
resection margins’’. ‘‘General outcomes’’ include those
affecting the whole body which cannot be attributed to a
certain body system, for example, fatigue, chills, flu-like
symptoms, malaise, anorexia, pain (unspecified, not associ-
ated with a particular body system), fever (not attributable
to infection), anthropometric measures (e.g., weight),
‘‘global’’ measures, ‘‘symptoms’’ (not associated with aparticular body system), ‘‘physical health’’, and fitness.
Laboratory parameters (e.g., from blood samples) and sci-
entific measures (e.g., pharmacokinetic outcomes) should
be classified within the physiological domain that captures
the reason for the assessment (rather than within the ‘‘blood
and lymphatic system’’ category, for example).
The functioning categories were extended beyond those
used by Smith et al. [11] (activities of daily living and psy-
chosocial) to differentiate more accurately between phys-
ical, social, role, emotional, and cognitive functioning.
The ‘‘delivery of care’’ domain contains a number of
variables related to health care interventions, including
compliance, withdrawal, and satisfaction. These were
grouped as they are all related to the appropriateness and
acceptability of the intervention and may not be easily
distinguishable (e.g., because of overlap between issues
relating to compliance, satisfaction with care, withdrawal,
treatment failure). Examples of outcomes in this category
include patient preference; withdrawal from intervention
(e.g., time to treatment failure, reason for stopping ther-
apy); appropriateness, accessibility, quality, and adequacy
of intervention; patient or carer satisfaction; and process,
implementation, and service outcomes.
The ‘‘adverse event’’ domain includes outcomes broadly
labeled as some form of unintended consequence of the
intervention (e.g., adverse events/effects, adverse reactions,
safety, harm, negative effects, toxicity, complications,
sequelae). Specifically named adverse events are classified
within the appropriate taxonomy domain relating to the
specific event type, with an additional level of categoriza-
tion which identifies this outcome as an adverse event.
The ‘‘mortality/survival’’ domain includes overall (all-
cause) and cause-specific survival/mortality, as well as com-
posite survival outcomes that include death (e.g., disease-
free survival). Composite outcomes should be classified in
all domains relating to each of the included event types; for
example, disease-free survival would be classified within
the ‘‘mortality/survival’’ domain as well as the physiological
outcome domain relating to the particular disease.
The final 38-item scale was applied to the classification of
trial outcomes recorded within the 299 published COS in the
COMET database that were published before 2016 and to
outcomes from 3,515 Cochrane reviews as part of the pilot
phase of the Cochrane Linked Data Project. To further illus-
trate its applicability, the taxonomy has been applied to out-
comes listed in 30 studies identified from a search of the US
National Institutes of Health clinical trials registry (www.
clinicaltrials.gov). Furthermore, two case studies are pre-
sented to demonstrate how the taxonomy can provide stan-
dard classification of outcomes across different research
settings linked to particular clinical areas. One of the authors
(S.D.) assessed all the outcomes in the COS database andNa-
tional Institutes of Health clinical trial registry. In cases of
any doubt or ambiguity, a second opinion (P.R.W.) was
sought. Cochrane review outcomes were classified by Co-
chrane reviewers.
Table 1. Development of 38-category scale
Core area Smith Williamson/Clarke (initial) Williamson/Clarke (revised)
Death 1: Mortality/survival 1: Mortality/survival 1: Mortality/survival
Physiological or clinical 2: Physiological/clinical 2: Physiological/clinical 2e24: Physiological/clinical
2: Blood and lymphatic system outcomes
3: Cardiac outcomes
4: Congenital, familial and genetic outcomes
5: Endocrine outcomes





11: Immune system outcomes
12: Infection and infestation outcomes
13: Injury and poisoning outcomes
14: Metabolism and nutrition outcomes
15: Musculoskeletal and connective tissue
outcomes
16: Outcomes relating to neoplasms: benign,
malignant and unspecified (including cysts
and polyps)
17: Nervous system outcomes
18: Pregnancy, puerperium, and perinatal
outcomes
19: Renal and urinary outcomes
20: Reproductive system and breast outcomes
21: Psychiatric outcomes
22: Respiratory, thoracic and mediastinal
outcomes
23: Skin and subcutaneous tissue outcomes
24: Vascular outcomes
3: Infection 3: Infection
4: Pain 4: Pain









6: Psychosocial 6: Psychosocial
7: Mental health
7: QoL 8: HRQL 30: Global quality of life
31: Perceived health status
8: Compliance 9: Compliance (including
withdrawal from treatment)
32: Delivery of care, including
- Satisfaction/patient preference
- Acceptability and availability
- Adherence/compliance
- Withdrawal from treatment
- Appropriateness of treatment





carer, health care provider)
10: Satisfaction
33: Personal circumstances













Adverse events 15: Adverse events/effects 12: Adverse events/effects 38: Adverse events/effects
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3.1. Literature review
A review of the literature identified several vocabularies
(such as MedDRA [E6], and SNOMED CT, [E7]) which
exist to organize and classify text relating to healthresearch, many of which are included within the Unified
Medical Language System (UMLS, [E8]). However, few
relate specifically to outcome classification. For example,
the ICF provides a conceptual framework for understanding
and describing health and disability, accounting for both
patient and contextual factors, rather than an explicit
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Headings (MeSH, the National Library of Medicine’s
controlled vocabulary thesaurus, [E9]) categories extend
beyond health outcomes, covering not only anatomy, dis-
eases, and health care but also technology, occupations, in-
formation science, geographicals and so forth. Subclasses
within their ‘‘diseases’’ category are similar to our physio-
logical/clinical domains but with additional levels of differ-
entiation, for example, between bacterial/virus/parasitic
diseases and occupational diseases/disorders of environ-
mental origin/chemically induced disorders.
Of those vocabularies that can be applied to outcomes,
none are suitable for the classification of all potential out-
comes from clinical trials, as they provide only a partial
perspective or are relevant only for specific diagnoses or
fields of research. For example, physiological domains
alone are categorized in some of these vocabularies, such
as ICD-10 [E4], NICE [E10], UK Clinical Research
Collaboration Health Research Classification System
Health Categories [E11], Patient-Centered Outcomes
Research Institute [E12], as well as in other ontologies
relating to genetic research (e.g., the Human Phenotypic
Ontology [E13], see Supplementary Table 2 on the jour-
nal’s web site at www.elsevier.com). The Diagnostic and
Statistical Manual of Mental Disorders (DSM, [E14]) pro-
vides a comprehensive classification system of mental dis-
orders only. The Grid-Enabled Measures (GEM) Database
[E15], an online tool for the organization of scientific mea-
sures used in behavioral, social science, and other scientific
research areas, classifies measures according to physiolog-
ical and methodological research areas. However, these cat-
egories do not cover the full range of potential trial
outcomes, and thus fail to provide a comprehensive struc-
ture for outcome classification.
The Agency for Healthcare Research and Quality
commissioned a project to determine existing methods to
standardize outcome measure definitions, in order to inform
the development of its Outcome Measures Framework
[E16]. Their literature review identified few existing
methods to categorize outcome measures, none of which
are entirely relevant for our purposes. For example, the Na-
tional Quality Form Quality Positioning System provides a
search facility for quality measures, with search categories
that extend beyond the remit of classifying trial outcomes
(see Supplementary Table 2 on the journal’s web site at
www.elsevier.com). The Outcome Measures Framework
provides a means to describe the context relating to
outcome measures within patient registry entries rather than
providing a comprehensive taxonomy structure for outcome
classification. This system provides a conceptual frame-
work to categorize data elements according to the charac-
teristics of the study (in particular, of the participant,
disease and treatment provider) and treatment (type and
intent), as well as of the outcome (categorized as survival,
disease response, events of interest, patient-reported out-
comes, and health system utilization). These five mainoutcome classification categories do not provide a compre-
hensive system for classifying all trial outcomes.
The literature review identified several outcome classifi-
cation systems; however, none of these provide a hierarchi-
cal structure of sufficient scope or granularity to be usefully
applied to all potential trial outcomes:
(i) Wilson and Cleary [12] developed a health-related
quality of life (HRQL) conceptual model rather than
providing a detailed outcome taxonomy structure
and excluded outcomes such as resource use or
adverse events.
(ii) Patient-Reported Outcomes Measurement Informa-
tion System (PROMIS, [E17]) provides a structure
for classifying patient-reported measures only; out-
comes collected by health care providers, and those
affecting wider society, are therefore not included.
(iii) Similarly, the Nursing Outcomes Classification
([E18]) only covers outcomes relevant to nursing,
thus excluding outcome domains with wider rele-
vance, such as resource use and adverse events.
(iv) Various disease-specific classification structures pro-
vide outcome taxonomies relevant to a specific dis-
ease or condition only (National Institutes of
Health Toolbox, DOMS, Neuro-QoL, ASCQ-Me,
[E19]).
(v) Outcome Measures in Rheumatology (OMERACT)
provides a useful structure of outcome ‘‘core areas,’’
with examples of domains to be included within each
of these ‘‘core areas’’; however, this structure is
not sufficiently detailed to provide standardized clas-
sification of outcomes beyond the top ‘‘core area’’
level [13].
(vi) Davey et al. [14] used a data-driven approach to cate-
gorize outcomes from Cochrane Reviews into 11 cat-
egories. The disadvantage of a data-driven approach
is that it potentially will not be fully comprehensive,
as it may not extend beyond the collected outcomes
to cover all possible trial outcomes. This structure
provided a useful starting point for classification of
trial outcomes but lacked a hierarchical structure;
some categories are overly broad while others are
too specific for classification purposes. Similarly,
Smith et al. [11] grouped outcomes from Cochrane
Reviews into 15 categories; however, this classifica-
tion system also failed to systematically differentiate
between higher level outcome types with a structured
hierarchy.
3.2. Outcome classification systems used in COS studies
One-third (99/299) of published COS studies involved a
systematic or literature review to identify relevant out-
comes. Of these, 21 applied their own data-driven approach
to outcome classification. Six applied an existing classifica-
tion system: four studies used ICF terms, one study used a
simplified version of the Wilson and Cleary model, and one
Table 2. Breakdown of outcomes within 299 COS in COMET database




Mortality/survival Mortality/survival 99 (33)
Physiological/clinical Physiological/clinical (1) 274 (92)
Blood and lymphatic system
outcomes
9 (3)




Endocrine outcomes 3 (1)
Ear and labyrinth outcomes 3 (1)
Eye outcomes 6 (2)
Gastrointestinal outcomes 43 (14)
General outcomes 57 (19)
Hepatobiliary outcomes 6 (2)














(including cysts and polyps)
33 (11)












Skin and subcutaneous tissue
outcomes
12 (4)
Vascular outcomes 31 (10)






Global quality of life 121 (40)
Perceived health status 0 (0)
Delivery of care 52 (17)
Personal circumstances 0 (0)
Resource use Resource use (1) 84 (28)
Economic 37 (12)
Hospital 24 (8)
Need for intervention 44 (15)
Societal/carer burden 5 (2)
Adverse
events/effects
Adverse events/effects 105 (35)
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(specifically for stroke outcomes) [15].
3.3. Categorization of COS outcomes
The newly proposed 38-item classification system was
applied to the 299 published COS in the COMET database,
where the median (range) number of outcomes per COS is
5 (1, 46). Table 2 displays the number of COS that include
at least one outcome from each of the categories. Ninety-
two percent (274 COS) include at least one physiological
outcome, whereas only 59% (177 COS) include at least
one measure of impact (HRQL or some measure of func-
tioning). Only one-third (105, 35%) of COS explicitly call
for adverse events/effects to be recorded. At least one
resource use outcome was included in only 84 (28%) of
COS. As expected, the breakdown according to physiolog-
ical/clinical domains largely reflects the profile of diseases
and conditions for which COS have been developed [5e7].
3.4. Categorization of systematic review outcomes
A total of 16,525 outcomes from 3,515 Cochrane
Reviews have been classified according to our taxonomy
to date as part of the pilot phase of the Cochrane Linked
Data Project (Table 3). The majority of the annotated
reviews came from the Cochrane Pregnancy and Childbirth
and the Neonatal groups; a smaller set came from the
Cochrane Developmental, Psychosocial and Learning Prob-
lems group. In these selected Cochrane reviews, outcomes
were less commonly reported within each of the over-
arching outcome areas than for COS, with the exception
of resource use. Less than one-quarter (831, 24%) of
reviews include a measure of impact (function or quality
of life, QoL) while physiological outcomes dominate, being
present in 83% (2,915) of reviews annotated to date.
3.5. Categorization of trial outcomes
The outcomes listed in 30 studies identified from a
search for randomized, phase 3 and 4 interventional studies
currently recruiting participants and received by the US
National Institutes of Health clinical trials registry,
clinicaltrials.gov, during the first 20 days of 2017 (https://
clinicaltrials.gov search terms ‘‘Randomized’’, ‘‘Phase
3,4’’, ‘‘Recruiting’’, ‘‘Interventional Studies’’, ‘‘Received
from January 1, 2017 to January 20, 2017’’) have been cate-
gorized in Supplementary Table 3 on the journal’s web site
at www.elsevier.com, demonstrating the general applica-
bility of our ontology to trials in a trials registry.
3.6. Case studies
3.6.1. Eczema
The taxonomy has been applied to the COS for
eczema [16]. In addition, the outcomes listed in eight
eczema studies identified from a search of clinicaltrials.gov (search terms ‘‘Randomized’’, ‘‘Phase 3,4’’, ‘‘Recruit-
ing’’, ‘‘Interventional Studies’’, ‘‘Eczema’’, no date restric-
tions) have been categorized in Supplementary Table 4 on
the journal’s web site at www.elsevier.com, demonstrating
the general applicability of our ontology to eczema trials.
Table 3. Cochrane Linked Data Project pilot phase outcome
classifications
Number (%) of 3,515
cochrane reviews
Number (%) of 16,525
outcome classifications
Adverse events 596 (17) 951 (6)
Mortality 857 (24) 1,246 (8)
Physiological 2,915 (83) 9,820 (59)
Function/QoL 831 (24) 1,844 (11)
Delivery of care 419 (12) 493 (3)
Resource use 1,117 (32) 2,171 (13)
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The taxonomy has been applied to the rheumatoid
arthritis (RA) COS [17]. The outcomes listed in 10 RA
studies identified from a search of clinicaltrials.gov (search
terms ‘‘Randomized’’, ‘‘Phase 3,4’’, ‘‘Recruiting’’, ‘‘Inter-
ventional Studies’’, ‘‘Rheumatoid Arthritis’’, ‘‘Received
from January 1, 2017 to January 20, 2017’’) have been cate-
gorized in Supplementary Table 5 on the journal’s web site
at www.elsevier.com, again demonstrating the general
applicability of our ontology to a particular clinical area.4. Discussion
A literature review identified several health research
vocabularies which extend beyond the remit of outcome
classification, as well as a number of outcome classification
systems. However, none of these are sufficiently compre-
hensive or granular for the specific purpose of classifying
all potential outcomes from clinical trials with structured
hierarchical differentiation between high level outcome
types. We have therefore described the development of a
new taxonomy that can be used for the classification of out-
comes included in all trials, COS, systematic reviews, and
trial registries. This classification system is based on similar
top level ‘‘core areas’’ common to other outcome hierar-
chies [12,13] but provides a more detailed taxonomy appro-
priate for all potential outcomes, in particular relating to
physiological, functioning, and resource use domains.
Health-related quality of life (HRQL) measurement
tools typically cover multiple domains (such as functioning,
resource use, general physiological health, and global qual-
ity of life) and should therefore be classified within each of
these domains, even when overall summary measures are
reported, as we would recommend for any composite
outcome. For example, see Supplementary Table 6 on the
journal’s web site at www.elsevier.com for the mapping be-
tween our taxonomy and the facets included in the
WHOQOL-100 tool [E20].
The ‘‘global quality of life’’ domain in our taxonomy is
reserved for specific individual questions or tools which
measure the implicit composite outcome of global QoL
(e.g., ‘‘How would you rate your overall quality of life?’’),
rather than for overall summary measures from HRQL tools
covering multiple domains. Comparison of our taxonomy
with the individual HRQL measures listed in Macefield[18] demonstrates that the vast majority of questions or
components included in HRQL tools should be classified
in domains other than global QoL. To further promote this
transparency relating to the content of HRQL measures, we
support the advice given by Macefield [18] that HRQL
tools should be split into their individual components. For
example, the Diabetes TherapyeRelated Quality of Life
Questionnaire can be split into various factors assessing
burden on social activities and daily activities; anxiety
and dissatisfaction; hypoglycemia; and treatment satisfac-
tion [19].
The PROMIS website [E17] groups its adult and pediat-
ric measures into profile domains in three core areas (phys-
ical, mental, and social health), along with specific domains
which act as search terms to identify relevant measures.
These patient-reported outcome domains can all be catego-
rized within various physiological and functioning domains
in our taxonomy, demonstrating the applicability of our tax-
onomy to another commonly used trial outcome resource.
Any specifically named adverse events (e.g., fatigue or
pain) should be categorized under the appropriate taxon-
omy domain, rather than within the adverse event domain.
In such cases, we would add an additional level of catego-
rization which specifies that this outcome was reported as
an adverse event. Thus, we suggest that our outcome
classification system should be implemented as a two-
component taxonomy, the first defining the outcome
structure (as we have specified in the 38-item scale) and
the second specifying whether or not the outcome is being
measured as a benefit or a harm outcome. For example, the
COS for colorectal cancer surgery [20] includes fecal
urgency, which is a potential adverse effect of the surgery.
In our system, this would be classified as a physiological
outcome, under the gastrointestinal category, but a second
component would identify it as an adverse outcome. In a
particular example of the detailed classification of adverse
events relating to total ankle arthroplasty [21], the adverse
events listed can be classified within existing physiological
categories, predominantly musculoskeletal and connective
tissue, and infection domains.
In contrast, the adverse event domain only includes out-
comes explicitly labeled as some form of unintended conse-
quence of the intervention, such as ‘‘adverse events,’’
‘‘adverse effects,’’ ‘‘adverse reactions,’’ ‘‘complications,’’
‘‘toxicity,’’ or ‘‘sequelae’’. This domain, which is not
intended to include any specifically named adverse events,
is important as it indicates whether or not trialists or
researchers considered the need to record events that may
not necessarily be prespecified ahead of time. Unless the
adverse event profile is very well established for a given
intervention, it is important that the incidence of all adverse
events, expected or otherwise, is reported. Similarly, COS
or systematic reviews that cover multiple intervention types
should address the potential for unspecified adverse events.
The resource use domains in our taxonomy map well to
those identified by Thorn et al. as key health economic
91S. Dodd et al. / Journal of Clinical Epidemiology 96 (2018) 84e92items to be collected as part of clinical trials [22]. The 10
items in their final core set are classified under different
types of care, all of which can be classified within our
resource use domains: ‘‘hospital care’’ or ‘‘emergency
care’’ fit within our ‘‘hospital’’ domain; ‘‘care at a general
practice surgery, health clinic or other community setting,’’
and ‘‘health care at home’’ belong to our ‘‘societal/carer
burden domain’’; and ‘‘medication’’ fits within our ‘‘need
for further intervention’’ domain.
We are confident that our taxonomy provides a suffi-
ciently comprehensive basis for the categorization of out-
comes included in clinical trials in general. However, we
would welcome feedback from researchers applying the
taxonomy in their clinical settings to demonstrate further
validation of the taxonomy or to highlight any necessary
changes. Note that we are not suggesting that trials or re-
views should necessarily include outcomes from each of
the core areas in this taxonomy. Note also that this taxon-
omy relates to outcomes measured at an individual-
patient level (including those relating to the direct impact
of the individual patient’s treatment or condition on wider
society, e.g., resource use or carer burden) but is not
intended to cover outcomes relating to the health or func-
tioning of wider society (e.g., family or community health).
Therefore, health promotion or public health outcomes
from trials of family- or community-based interventions
can be classified using our taxonomy if they relate to an in-
dividual’s condition or care, but not if they are measured at
the family or community level.
Outcome categories within our taxonomy may be classi-
fied in even greater detail in relation to particular interven-
tions (e.g., the classification of outcomes for childhood
vaccination communication interventions [23]). Indeed,
we would encourage further subdivision of each outcome
domain by researchers specializing in relevant clinical or
methodological areas. There may be existing taxonomies
that could be used to provide finer classification within
our high-level taxonomy domains; for example, the DSM
could be used to classify mental disorders within the psy-
chiatry domain.
Adoption of this classification system will facilitate liter-
ature searches; for example, if clinical trial outcomes were
routinely classified according to this taxonomy, researchers
would easily be able to identify clinical trials that included
outcomes domains from a particular COS. A readily avail-
able taxonomy will also assist COS developers who need to
categorize outcomes, for example as part of their Delphi
survey, thereby speeding up the development of COS and
expediting their completion and availability for use by tria-
lists and other researchers. Application of this classification
system to COS contained within the COMET database has
highlighted key points to note, including that, although the
COMET database relates to COS recommended for effec-
tiveness trials, far fewer of the COS contain measures of
impact (58%) than physiological outcomes (92%). Further-
more, only one-third of COS reports highlight the need torecord unintended adverse consequences, and even fewer
COS (29%) include any economic outcomes.
The lack of a standard taxonomy relating to trial out-
comes impedes the ability to efficiently and effectively
search the literature. An accepted taxonomy of outcomes
would increase the reuse value of outcome data, just as
MeSH terms have transformed the searchability of medical
literature. The taxonomy would initially help drive to push
for consistency of clinical outcome terms between clinical
trials, which has been a major focus of the COMET initia-
tive. More importantly it will allow efficient searching, re-
porting, and classification of clinical outcomes for the first
time, thereby speeding up research activities including dis-
covery science and ‘‘big data’’ approaches to extracting
knowledge from published information.
In summary, the applicability of this new taxonomy has
been demonstrated for the categorization of outcomes from
COS, systematic reviews, and trials recorded within a clin-
ical trial registry. Similarly, two case studies demonstrate
the relevance of standardizing outcome classification to
link COS, Cochrane Reviews, and trial registry entries
within particular clinical areas. This taxonomy has been de-
signed with the purpose of providing high-level differenti-
ation between outcome domains to facilitate uniformity
of outcome classification in electronic databases. We would
welcome further testing of this taxonomy, and further
development of subcategories to provide finer classification
within each of the outcome domains is encouraged.
Ongoing COS studies have used this taxonomy to classify
outcomes for their initial list for a Delphi survey
[E21eE23]. We will monitor the use of the taxonomy
and collate feedback, to be subsequently reported.Acknowledgement
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